Table 1.
Baseline Demographic, Clinic-Pathological and Prognostic Characteristics for Prostate-Cancer Patients Receiving IMRT with (Arm-A) or without Daily Image-Guidance (Arm-B)
| Characteristic | Arm-A | Arm-B | P-value |
|---|---|---|---|
| (N= 72; 28%) | (N= 185; 72%) | ||
| Median follow up (years) | 3.7 (range 3.3-4.1) | 11.2 (range 7-14.6) | <0.001 |
| Median age (years) | 71 (range 50-85) | 73 (range 48-85) | 0.7 |
| African-American race | 34 (47.2%) | 103 (55.7%) | 0.22 |
| Ever smoker (current/ex-smoker) | 45 (62.5%) | 120 (64.9%) | 0.72 |
| Alcohol use | 0.41 | ||
| Social | 17 (23.6%) | 58 (31.4%) | |
| Frequent/abuse | 11 (15.3%) | 30 (16.2%) | |
| Median baseline CCI score | 2 (0-9) | 1 (0-7) | 0.84 |
| Median AUA /IPSS score at diagnosis | 5.0 (2.0-9.0) | 5.0 (2.0-10.0) | 0.14 |
| PSA level at diagnosis (ng/dl) | 11.1 ± 8.9 | 12.2 ± 10.3 | 0.39 |
| Grade Group | 0.014 | ||
| 1 (3+3) or 2 (3+4) | 39 (54.2%) | 109 (58.9%) | |
| 3 (4+3) | 18 (25%) | 29 (15.7%) | |
| 4 (4+4, 3+5 & 5+3) or 5 (4+5, 5+4 & 5+5) | 15 (20.8%) | 47 (25.4%) | |
| Median number of positive cores | 4.0 (range 1.0-13.0) | 5.0 (range 1.0-18.0) | 0.14 |
| Mean percentage of positive cores | 42.0 ± 25.5 | 66.6 ± 26.4 | <0.001 |
| Clinical T-stage | 0.48 | ||
| T1b-T2c | 69 (95.8%) | 182 (98.4%) | |
| T3a-b | 3 (4.2%) | 3 (1.6%) | |
| NCCN risk group | 0.41 | ||
| Intermediate | 51 (70.8%) | 121 (65.4%) | |
| High | 21 (29.2%) | 64 (34.6%) | |
| Median UCSF-CAPRA score at diagnosis | 5.0 (2.0-9.0) | 5.0 (2.0-10.0) | 0.14 |
IMRT, Intensity-Modulated Radiation Treatment; CCI, Charlson Comorbidity-Index; IPSS/AUA, International Prostate Symptom Score / American Urological Association; PSA, Prostatic Specific Antigen; NCCN, National Comprehensive Cancer Network; UCSF-CAPRA, University of California, San Francisco Cancer of the Prostate Risk Assessment